Dimensional Fund Advisors LP Grows Position in Kura Oncology, Inc. (NASDAQ:KURA)

Dimensional Fund Advisors LP grew its stake in shares of Kura Oncology, Inc. (NASDAQ:KURA – Get Rating) by 14.0% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,572,657 shares of the company’s stock after buying an additional 193,042 shares during the period. Dimensional Fund Advisors LP owned 2.35% of Kura Oncology worth $21,482,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the stock. Guggenheim Capital LLC boosted its holdings in shares of Kura Oncology by 3.8% during the first quarter. Guggenheim Capital LLC now owns 24,671 shares of the company’s stock worth $397,000 after purchasing an additional 914 shares during the last quarter. Legal & General Group Plc boosted its holdings in shares of Kura Oncology by 6.4% during the second quarter. Legal & General Group Plc now owns 20,467 shares of the company’s stock worth $376,000 after purchasing an additional 1,225 shares during the last quarter. Nisa Investment Advisors LLC boosted its holdings in shares of Kura Oncology by 80.8% during the second quarter. Nisa Investment Advisors LLC now owns 3,290 shares of the company’s stock worth $60,000 after purchasing an additional 1,470 shares during the last quarter. Raymond James & Associates boosted its holdings in shares of Kura Oncology by 18.6% during the first quarter. Raymond James & Associates now owns 17,598 shares of the company’s stock worth $283,000 after purchasing an additional 2,757 shares during the last quarter. Finally, Great West Life Assurance Co. Can acquired a new position in Kura Oncology in the third quarter valued at $39,000.

Kura Oncology Stock Down 3.7 %

Shares of NASDAQ KURA opened at $11.34 on Tuesday. Kura Oncology, Inc. has a 1 year low of $10.41 and a 1 year high of $19.93. The firm has a market cap of $776.11 million, a price-to-earnings ratio of -5.59 and a beta of 0.93. The company has a debt-to-equity ratio of 0.02, a quick ratio of 18.56 and a current ratio of 18.56. The stock’s 50-day simple moving average is $12.73 and its 200-day simple moving average is $13.88.

Kura Oncology (NASDAQ:KURA – Get Rating) last announced its earnings results on Thursday, February 23rd. The company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.09. As a group, equities analysts anticipate that Kura Oncology, Inc. will post -2.38 earnings per share for the current fiscal year.

Insider Activity at Kura Oncology

In related news, COO Kathleen Ford sold 1,821 shares of the business’s stock in a transaction dated Friday, January 27th. The stock was sold at an average price of $13.89, for a total value of $25,293.69. Following the completion of the sale, the chief operating officer now directly owns 21,214 shares of the company’s stock, valued at $294,662.46. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In related news, insider Kirsten Flowers sold 1,906 shares of the business’s stock in a transaction dated Friday, January 27th. The stock was sold at an average price of $13.89, for a total value of $26,474.34. Following the completion of the sale, the insider now directly owns 20,605 shares of the company’s stock, valued at $286,203.45. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Kathleen Ford sold 1,821 shares of the business’s stock in a transaction dated Friday, January 27th. The shares were sold at an average price of $13.89, for a total value of $25,293.69. Following the completion of the sale, the chief operating officer now directly owns 21,214 shares of the company’s stock, valued at $294,662.46. The disclosure for this sale can be found here. Insiders sold a total of 5,275 shares of company stock valued at $73,270 over the last three months. 5.40% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $32.00 target price on shares of Kura Oncology in a report on Friday, February 24th. Stifel Nicolaus started coverage on Kura Oncology in a research note on Monday, January 30th. They set a “buy” rating and a $25.00 price objective on the stock. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $31.20.

Kura Oncology Company Profile

(Get Rating)

Kura Oncology, Inc operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias.